ESR1 and breast cancer: As a result, Orai1α is the only Orai1 variant responsible for in vitro calcification mediated by SPCA2 in MCF-7 cells, which suggest that Orai1α might be considered as a specific therapeutic target in the treatment of ER+ breast cancer.